Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy — TNF-VAX  

Pneumococcal Vaccine Clinical Trial

Official title: Pneumococcal Vaccination in Patients With Anti-TNF Alpha Therapy: Status Report on the NOVO Hospital - Pontoise Site

Status Completed

Clinical Trial Summary

As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital. The aim of this study is to assess the status of pneumococcal vaccination in patients at the NOVO hospital - Pontoise site, who have received anti-TNF alpha therapy.

Clinical Trial Description

Immunosuppressed patients are at risk of infections, sometimes severe with life-threatening consequences. Some of these are vaccine-preventable, notably pneumococcal infections. Specific vaccination recommendations have been published since 2012 by the French High Council for Public Health. However, vaccine coverage is below the desired immunisation objectives for immunosuppressed patients. As the vaccination of immunosuppressed people is insufficiently performed in France, it seems interesting to carry out an evaluation of the situation on the site of the NOVO - Pontoise hospital, in order to propose, if necessary, measures, in particular a specialised consultation, with the aim of improving the vaccination coverage of this population at risk The aim of this study is to assess the status of pneumococcal vaccination in patients who have received anti-TNF alpha therapy. ;

Related Conditions & MeSH terms

• Pneumococcal Vaccine

• NCT number: NCT05788510
• Study type: Observational
• Source: Centre Hospitalier René Dubos
• Status: Completed
• Start date: April 3, 2023
• Completion date: May 6, 2023